🇮🇳 Biocon Ltd
Get Biocon Ltd filings on Telegram the moment they are published.
Follow Biocon Ltd on TelegramOne tap starts your 30-day free trial. No card needed.
Overview: U.S. FDA has approved Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta for HER2-positive breast cancer, with a planned U.S. launch in Q3 2028.
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest